• Statutory instrument 2004/1031: The Medicines for Human Use (Clinical Trials) Regulations 2004.
• Statutory Instrument 2006/1928: The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006.
Notified by: Issue: Would MHRA have expected this case to be notified?
Sponsor Dosing error. Ethics Committee & MHRA informed. Subjects withdrawn. The sponsor stated that there were no serious consequences to subjects or data. No, if there was no significant impact on the integrity of trial subjects or on scientific validity of the trial.
Sponsor Patient Information Leaflet and Informed Consent updated. At one trial site this was not relayed to the patients until approximately 2-3 months after approval. More information on the potential consequences of the delay should have been provided. Possibly not. If this was not a systematic or persistent problem and if no harm to trial subjects resulted from the delay.
Yes, if there was a significant impact on the integrity of trial subjects.
Sponsor Visit date deviation. A common deviation in clinical trials. No. Minor protocol deviation, which does not meet the criteria for notification.
Contractor Investigator failed to report a single SAE as defined in the protocol (re-training provided). No, if it did not result in this or other trial subjects being put at risk, and if it was not a systematic or persistent problem.
In some circumstances, failure to report a SUSAR could have a significant impact on trial subjects. Sufficient information should be provided for the impact to be assessed.
Identified during inspection prior to the current requirement to report serious breaches Investigator site failed to reduce or stop trial medication, in response to certain laboratory parameters, as required by the protocol. This occurred with several patients over a one year period, despite identification by the monitor of the first two occasions. Patients were put at increased risk of thrombosis. Yes, under the current requirements, this should have been reported as a serious breach.
Sponsor Becomes aware of fraud at investigator site in the UK, which does not affect the overall scientific value of the Sponsor’s trial or the integrity of trial subjects in the UK. However, the Sponsor is aware that the fraudster was involved in trials being sponsored by other organisations. Although, in this situation, not a legal requirement under 29A, MHRA encourages voluntary reporting of all fraud cases in the UK, because MHRA will wish to establish the impact on the other trials in case subject integrity or the scientific value of those trials was compromised.
Notification of Serious Breach of Good Clinical Practice or the Trial Protocol
(Ref: UK Statutory Instrument 2006:1928, Regulation 29A)
Your Contact Details:
Date Breach Identified by Sponsor:
Details of Individual or Organisation committing breach:
Details of related study (e.g. study title, EudraCT No) if applicable:
Please give details of the breach. Where possible, please include your rationale (e.g. patient safety / data integrity issue and relevant legislation if known).
(continue on additional sheets if required)
Please give details of action taken:
(continue on additional sheets if required)
FOR MHRA USE ONLY:
GCP Ref Number:
Please forward this notification to [email protected] OR GCP Inspectorate, MHRA, 18-103, Market Towers, 1 Nine Elms Lane, London, SW8 5NQ.
Upcoming Clinical Trials
NCT04553861Not yet recruitingConditions: Blood Pressure
NCT04553874Not yet recruitingConditions: the Health Status of the Oldest Old
NCT04553887Not yet recruitingAlmonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II TrialConditions: Non Small Cell Lung Cancer
NCT04553926Not yet recruitingConditions: Ovarian Cancer; Breast Cancer
NCT04553939Not yet recruitingNeoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder CancerConditions: Urothelial Carcinoma; Bladder Cancer
NCT04553965Not yet recruitingAssessment of Alveolar Bone Thickness Buccal to Maxillary Anterior and Premolar Teeth in a Sample of Egyptian Population Using CBCTConditions: Alveolar Bone Thickness
NCT04554056Not yet recruitingConditions: Breast Cancer Female
NCT04554069Not yet recruitingEffect of Different Antihypertensive Treatment on Serum Uric Acid in Newly Diagnosed Hypertensive PatientsConditions: Hypertension
NCT04554095Not yet recruitingDevelopment of a Multimodal Index to Improve the Predictive Value of Success in Weaning From Mechanical VentilationConditions: Weaning Failure; Mechanical Ventilation Complication
NCT04554108Not yet recruitingAcute Non-severe Osteomyelitis in Children - Outpatient Management Strategy With Oral Antibiotic Therapy Compared to a Standard Strategy With Conventional Hospitalization and Intravenous Antibiotic Therapy: a Randomized Open-label Non-inferiority Study With Bayesian and Medical-economic Analyses.Conditions: Osteomyelitis
Recent CRA jobs
PV - Operations Specialist
Operations Analyst 1
Regulatory & Start Up Specialist 1
Mgr, Clinical Operations
Global Manager, Site Identification and Site Relations (Home-Based) – IQVIA Biotech
Principal Statistical Programmer (Onc)
Principal - Enriched Studies
Study Start-Up Specialist (Italy, home-based) - IQVIA Biotech
Site Engagement & Optimization, Specialist
Site Engagement & Optimization, Project Manager / Lead (Home or Office-based)